国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水

 
Guideview > FDA
  • Will the Biosecure act passed during lame duck session?
    Will the Biosecure act passed during lame duck session? Biosecure Act Get insights into the anticipated passage of the Biosecure Act during Congress's lame-duck session. With bipartisan support and strategic amendments, experts predict a high likelihood of success.
  • Next Domestic Big Drug
    Next Domestic Big Drug Astellas Astellas has secured FDA approval for Zolbetuximab, the first Claudin18.2-targeted antibody for advanced HER2-negative gastric cancer. This breakthrough opens a new market, addressing a critical need in cancer treatment and forecasting substantial sales growth in the coming years.
  • FDA Approved Summay - September 2024
    FDA Approved Summay - September 2024 FDA latest FDA drug approvals from September 2024, featuring groundbreaking treatments like Fresenius Kabi's Otulfi for inflammatory diseases, Dupixent for COPD, and innovative therapies for rare conditions.
  • Studying FDA Major Deficiencies to Support the Export or Successful Registration of Domestic Medicines
    Studying FDA Major Deficiencies to Support the Export or Successful Registration of Domestic Medicines FDA Learn how studying FDA major deficiencies can enhance drug research and registration success in China. Explores FDA standards, common deficiencies, and solutions to improve formulations, compliance, and export potential for Chinese pharmaceutical products in global markets.
  • FDA approves AbbVie's 24-hour subcutaneous infusion therapy
    FDA approves AbbVie's 24-hour subcutaneous infusion therapy AbbVie The FDA has approved AbbVie’s VYALEV (ABBV-951), a 24-hour continuous subcutaneous infusion therapy for advanced Parkinson's disease. This first-of-its-kind treatment, based on levodopa, offers significant improvements in motor fluctuations and prolongs "on" time with fewer complications.
  • FDA Approves Roche's PI3Kα Inhibitor - Doubled PFS!
    FDA Approves Roche's PI3Kα Inhibitor - Doubled PFS! FDA The FDA approved Genentech's PI3Kα inhibitor, Inavolisib (Itovebi), in combination with palbociclib and fulvestrant for advanced breast cancer patients with PIK3CA mutations. The therapy showed a significant 57% reduction in disease progression in the Phase III INAVO120 trial.
  • FDA Approves Zenrelia for Itch Control in Dogs with Allergies
    FDA Approves Zenrelia for Itch Control in Dogs with Allergies FDA FDA Approves Zenrelia for Itch Control in Dogs with Allergies. Zenrelia (ilunocitinib tablets) is a new FDA-approved medication for managing pruritus and allergic dermatitis in dogs aged one year and older
  • FDA Grants First Approval for Niemann-Pick Disease, Type C Treatment
    FDA Grants First Approval for Niemann-Pick Disease, Type C Treatment FDA The FDA has approved Miplyffa (arimoclomol) as the first-ever treatment for Niemann-Pick disease, type C (NPC), a rare genetic disorder that causes severe neurological symptoms and organ dysfunction.
  • FDA Approves Filsuvez?: Birch Triterpenes Gel for EB
    FDA Approves Filsuvez?: Birch Triterpenes Gel for EB FDA FDA approved Amryt Pharma’s Filsuvez? (Birch Triterpenes Gel) for treating Junctional and Dystrophic Epidermolysis Bullosa in patients 6 months and older. Filsuvez? is now a recognized Orphan Drug, Rare Pediatric Disease, and Fast Track therapy, following its EMA approval in June 2022.
  • FDA Approves Durvalumab for Neoadjuvant NSCLC Treatment
    FDA Approves Durvalumab for Neoadjuvant NSCLC Treatment FDA The FDA has approved durvalumab (Imfinzi) for use with platinum-based chemotherapy as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC). The regimen, followed by adjuvant durvalumab post-surgery, shows improvement in event-free survival and pathological complete response.
延寿县| 叙永县| 全州县| 荣昌县| 中方县| 郎溪县| 宣武区| 黄平县| 通山县| 临海市| 香港| 萨迦县| 昌乐县| 开原市| 雅江县| 兴国县| 保亭| 遂溪县| 繁峙县| 眉山市| 商都县| 都匀市| 沈阳市| 宜州市| 中超| 电白县| 和平区| 邵东县| 前郭尔| 嘉善县| 海口市| 台南市| 漳州市| 台江县| 宁夏| 河北省| 新昌县| 什邡市| 苗栗县| 万安县| 安国市|